Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adjuvant therapy for colon cancer.

Jeffrey Cilley1, Mary F Mulcahy

  • 1Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 North Saint Clair, Suite 850, Chicago, IL 60611, USA.

Current Oncology Reports
|April 19, 2006
PubMed
Summary

Colon cancer treatments are evolving with new drugs like oxaliplatin and capecitabine improving efficacy. However, adjuvant therapy benefits for stage II colon cancer remain small and insignificant, prompting research into biologic agents and predictive markers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201.

The oncologist·2025
Same author

Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinoma.

The oncologist·2025
Same author

Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2025
Same author

A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers.

Cancer·2025
Same author

NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024.

Journal of the National Comprehensive Cancer Network : JNCCN·2024
Same author

Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

Journal of the National Comprehensive Cancer Network : JNCCN·2024

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Colon cancer is a significant cause of cancer mortality globally.
  • Current adjuvant therapy often relies on 5-fluorouracil, with newer agents like oxaliplatin and capecitabine enhancing treatment efficacy.

Purpose of the Study:

  • To review current adjuvant therapy for colon cancer.
  • To discuss the efficacy of novel therapeutic agents and future research directions.

Main Methods:

  • Literature review of colon cancer treatment advancements.
  • Analysis of adjuvant therapy benefits in stage II disease.
  • Exploration of biologic agents and prognostic markers.

Main Results:

  • Adjuvant therapy for stage II colon cancer shows limited and often statistically insignificant benefits.

Related Experiment Videos

  • Oxaliplatin and capecitabine represent advancements in colon cancer treatment efficacy.

    • Conclusions:

    • Further research is needed to identify patient populations who benefit from adjuvant therapy.
    • Biologic agents and predictive markers are crucial for future colon cancer treatment strategies.